“The fund initiated a position in Indivior at an attractive valuation of 10x expected earnings after a guidance cut caused a temporary stock drop. The manager expects an upcoming sNDA approval in February for an improved dosing regimen to counter competitive threats and restore market share.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.